BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-02-19 07:00 |
BerGenBio har fullført rekruttering av pasienter til første halvdel av Fase II-…
|
Norwegian | 7.1 KB | ||
| 2018-02-16 12:50 |
BerGenBio ASA: Notice of extraordinary general meeting
|
Norwegian | 197.2 KB | ||
| 2018-02-16 12:50 |
BerGenBio ASA: Notice of extraordinary general meeting
|
English | 1.6 KB | ||
| 2018-02-13 07:00 |
BerGenBio ASA: Exercise of employee share options and increase of capital
|
Norwegian | 44.0 KB | ||
| 2018-02-13 07:00 |
BerGenBio ASA: Exercise of employee share options and increase of capital
|
English | 2.0 KB | ||
| 2018-02-13 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
|
Norwegian | 59.9 KB | ||
| 2018-02-13 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
|
Norwegian | 2.4 MB | ||
| 2018-02-13 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
|
Norwegian | 725.0 KB | ||
| 2018-02-13 06:00 |
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
|
English | 9.8 KB | ||
| 2018-02-13 06:00 |
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
|
Norwegian | 63.1 KB | ||
| 2018-02-13 06:00 |
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
|
Norwegian | 725.0 KB | ||
| 2018-02-13 06:00 |
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
|
Norwegian | 2.4 MB | ||
| 2018-02-13 06:00 |
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
|
Norwegian | 10.5 KB | ||
| 2018-02-06 07:00 |
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presenta…
|
Norwegian | 44.4 KB | ||
| 2018-02-06 07:00 |
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presenta…
|
English | 2.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
